More articles from Therapeutic Agents: Biological: Poster Presentations - Proffered Abstracts

Abstract B120: TAK-164, a GCC-targeted antibody-drug conjugate (ADC) for the treatment of colorectal cancers and other GI malignancies
Adnan O. Abu-Yousif, Bret M. Bannerman, Donna Cvet, Melissa Gallery, Michelle L. Ganno, Michael D. Smith, Katharine C. Lai, Thomas A. Keating, Jayaprakasam Bolleddula, Bradley Stringer, Mark G. Qian, Afrand Kamali, Kurt Eng, Secil Koseoglu, Cindy Q. Xia, O. Petter Veiby

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B120; DOI: 10.1158/1535-7163.TARG-17-B120
Abstract B105: ACTR707: a novel T-cell therapy for the treatment of relapsed or refractory CD20+ B cell lymphoma in combination with rituximab
Greg Motz, Kathleen Whiteman, John Shin, Tapasya Pai, Casey Judge, Anthony Barnitz, James Hemphill, James Kim, Ann Ranger, Heather Huet, Kathleen McGinness, Birgit Schultes, Geoffrey Hodge, Michael Vasconcelles, Seth Ettenberg

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B105; DOI: 10.1158/1535-7163.TARG-17-B105
Abstract LB-B25: Preliminary phase I data comparing HuMab-5B1 (MVT-5873), a monoclonal antibody targeting sLea, as a single agent and in combination with first line nab-paclitaxel and gemcitabine in patients with CA19-9 positive pancreatic cancer
Eileen Mary O'Reilly, Judy Sing-Zan Wang, Kenneth H. Yu, Maeve Aine Lowery, Anna M. Varghese, Johanna C. Bendell, Erkut Hasan Borazanci, Hayley Estrella, Kimberly Fowler, Mariella Hoskins, Stephanie Bussen, Teresa J. Melink, Christine M. Kearns, H Toni Jun, Paul W. Maffuid, John C. Gutheil, Todd Michael Bauer

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) LB-B25; DOI: 10.1158/1535-7163.TARG-17-LB-B25
Abstract B113: Development of a novel synthetic consensus DNA vaccine that targets multiple MAGE-A family members for anticancer immune therapy
Elizabeth K. Duperret, Aspen Trautz, Megan Paik, Charles Reed, Jian Yan, David B. Weiner

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B113; DOI: 10.1158/1535-7163.TARG-17-B113
Abstract B121: The benefits of bispecific mAb² antibodies targeting EGFR and HGF
Kin-Mei Leung

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B121; DOI: 10.1158/1535-7163.TARG-17-B121
Abstract B107: Antitumor activity of new antibody-drug conjugate with eribulin in triple-negative breast cancer PDX
Marc Hillairet de Boisferon, Caroline Mignard, Coralie Durix, Toshimitsu Uenaka, Katherine Rybinski, Xin Cheng, Keiji Furuuchi, Eart Albone

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B107; DOI: 10.1158/1535-7163.TARG-17-B107
Abstract B103: A multi-analyte HPLC-MS/MS approach to assessing exposure of a Probody drug conjugate in preclinical studies
Laura Serwer, Shweta Singh, Claus Krebber, Shouchun Liu, Niharika Chauhan, Robert Leanna, Hong Lu, Ilaria Badagnani, Tracy Henriques, Susan Morgan-Lappe, William Mylott, Sridhar Viswanathan, Jennifer Richardson, Michael Kavanaugh

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B103; DOI: 10.1158/1535-7163.TARG-17-B103
Abstract B109: ASN004, a novel 5T4-targeted Dolaflexin ADC, causes complete and durable tumor regression in a variety of tumor xenograft models
Roger A. Smith, David J. Zammit, Sanjeeva P. Reddy

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B109; DOI: 10.1158/1535-7163.TARG-17-B109
Abstract B114: Humanized anti-Sialyl-Tn monoclonal antibody-drug conjugates inhibit tumor growth in vitro and in vivo
Daniel Dransfield, Jillian M. Prendergast, David A. Eavarone, Rawan Nazer, Linah Al-Alem, Bo Rueda, Jenna Stein, Jeff Behrens

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B114; DOI: 10.1158/1535-7163.TARG-17-B114
Abstract B118: Potentiation of IL-2’s antitumor efficacy without compromised tolerability by a novel human antibody
Kirk Johnson, Ou Li, Xiaohe Liu, Lucia Beviglia

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B118; DOI: 10.1158/1535-7163.TARG-17-B118

Main menu

User menu

Search

More articles from Therapeutic Agents: Biological: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About MCT